Literature DB >> 32430295

Regulatory B Cells Normalize CNS Myeloid Cell Content in a Mouse Model of Multiple Sclerosis and Promote Oligodendrogenesis and Remyelination.

Andrea Pennati1, Emily A Nylen1, Ian D Duncan2, Jacques Galipeau3.   

Abstract

The unmet medical need of patients with multiple sclerosis (MS) is the inexorable loss of CNS myelin and latterly neurons leading to permanent neurologic disability. Solicitation of endogenous oligodendrocytes progenitor cells, the precursor of oligodendrocytes, to remyelinate axons may abort the onset of disability. In female mice with experimental autoimmune encephalomyelitis (EAE), a murine model of MS, adoptive transfer of IL-10+ regulatory B cells (Bregs) has been shown to reverse EAE by promoting the expansion of peripheral and CNS-infiltrating IL-10+ T cells. Here, we examined whether Bregs treatment and its bystander effect on regulatory T cells are associated with CNS repair as reflected by oligodendrogenesis and remyelination. We have found that transfusion of Bregs reverses established clinical EAE and that clinical improvement is associated with a significant increase in spinal cord remyelination as reflected by g-ratio analysis within the thoracic and lumbar spine. We further observed in the spinal cords of EAE Bregs-treated mice that CNS resident CD11b/CD45intLy6C- microglia, and infiltrating CD11b+/CD45high monocytes/macrophages content reverts to normal and polarize to a M2-like CD206+ phenotype. Concurrently, there was a substantial increase in neo-oligodendrogenesis as manifest by an increase in CD45-/low CNS cells expressing A2B5, an early marker in oligodendrocytes progenitor cell differentiation as well as GalC+/O1+ premyelinating and myelin basic protein+/myelin oligodendrocyte glycoprotein+ mature oligodendrocytes with reciprocal downregulation of paired related homeobox protein 1. These results demonstrate that the clinical benefit of Bregs is associated with normalization of CNS immune milieu and concurrent activation of oligodendrocyte progenitor cells with subsequent remyelination.SIGNIFICANCE STATEMENT In multiple sclerosis patients, demyelination progresses with aging and disease course, leading to irreversible disability. In this study, we have discovered, using a mouse model of multiple sclerosis, that the transfusion of autologous regulatory B cells (Bregs) is able to ameliorate, cure, and sustain the durable remission of the disease. We show that the adoptive transfer of Bregs dramatically decreased the frequency of myeloid-derived cells, both infiltrating monocytes/macrophages and resident microglia, and converted their phenotype to an immunosuppressive-like phenotype. Moreover, we showed that CNS oligodendrocyte progenitor cells are activated following Bregs treatment and differentiate into myelinating oligodendrocytes, which results in neo-oligodendrogenesis and remyelination of spinal cords.
Copyright © 2020 the authors.

Entities:  

Keywords:  Bregs; myelin; oligodendrocytes; remyelination

Mesh:

Year:  2020        PMID: 32430295      PMCID: PMC7314404          DOI: 10.1523/JNEUROSCI.2840-19.2020

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  43 in total

Review 1.  Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis.

Authors:  Jens Ingwersen; Orhan Aktas; Hans-Peter Hartung
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

2.  Induction and blockage of oligodendrogenesis by differently activated microglia in an animal model of multiple sclerosis.

Authors:  Oleg Butovsky; Gennady Landa; Gilad Kunis; Yaniv Ziv; Hila Avidan; Nadav Greenberg; Adi Schwartz; Igor Smirnov; Ayala Pollack; Steffen Jung; Michal Schwartz
Journal:  J Clin Invest       Date:  2006-03-23       Impact factor: 14.808

3.  Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression.

Authors:  Takashi Matsushita; Koichi Yanaba; Jean-David Bouaziz; Manabu Fujimoto; Thomas F Tedder
Journal:  J Clin Invest       Date:  2008-10       Impact factor: 14.808

Review 4.  Safety concerns and risk management of multiple sclerosis therapies.

Authors:  P Soelberg Sorensen
Journal:  Acta Neurol Scand       Date:  2016-11-27       Impact factor: 3.209

Review 5.  Mechanical plasticity during oligodendrocyte differentiation and myelination.

Authors:  Helena S Domingues; Andrea Cruz; Jonah R Chan; João B Relvas; Boris Rubinstein; Inês Mendes Pinto
Journal:  Glia       Date:  2017-09-21       Impact factor: 7.452

Review 6.  Role of pro-inflammatory cytokines released from microglia in Alzheimer's disease.

Authors:  Wen-Ying Wang; Meng-Shan Tan; Jin-Tai Yu; Lan Tan
Journal:  Ann Transl Med       Date:  2015-06

7.  An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis.

Authors:  L B Nicholson; J M Greer; R A Sobel; M B Lees; V K Kuchroo
Journal:  Immunity       Date:  1995-10       Impact factor: 31.745

8.  Functional differences between microglia and monocytes after ischemic stroke.

Authors:  Rodney M Ritzel; Anita R Patel; Jeremy M Grenier; Joshua Crapser; Rajkumar Verma; Evan R Jellison; Louise D McCullough
Journal:  J Neuroinflammation       Date:  2015-05-29       Impact factor: 8.322

9.  Maltose-binding protein fusion allows for high level bacterial expression and purification of bioactive mammalian cytokine derivatives.

Authors:  Andrea Pennati; Jiusheng Deng; Jacques Galipeau
Journal:  PLoS One       Date:  2014-09-08       Impact factor: 3.240

10.  Characterization of oligodendroglial populations in mouse demyelinating disease using flow cytometry: clues for MS pathogenesis.

Authors:  Andrew P Robinson; Jane M Rodgers; Gwendolyn E Goings; Stephen D Miller
Journal:  PLoS One       Date:  2014-09-23       Impact factor: 3.240

View more
  9 in total

1.  Neuroretinal-Derived Caveolin-1 Promotes Endotoxin-Induced Inflammation in the Murine Retina.

Authors:  Jami M Gurley; Grzegorz B Gmyrek; Mark E McClellan; Elizabeth A Hargis; Stefanie M Hauck; Mikhail G Dozmorov; Jonathan D Wren; Daniel J J Carr; Michael H Elliott
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-10-01       Impact factor: 4.799

2.  Lesion stage-dependent causes for impaired remyelination in MS.

Authors:  Katharina Heß; Laura Starost; Nicholas W Kieran; Christian Thomas; Maria C J Vincenten; Jack Antel; Gianvito Martino; Inge Huitinga; Luke Healy; Tanja Kuhlmann
Journal:  Acta Neuropathol       Date:  2020-07-24       Impact factor: 17.088

Review 3.  Advances of Regulatory B Cells in Autoimmune Diseases.

Authors:  Qiugang Zhu; Ke Rui; Shengjun Wang; Jie Tian
Journal:  Front Immunol       Date:  2021-04-15       Impact factor: 7.561

4.  Treatment With CD52 Antibody Protects Neurons in Experimental Autoimmune Encephalomyelitis Mice During the Recovering Phase.

Authors:  Wenlin Hao; Qinghua Luo; Michael D Menger; Klaus Fassbender; Yang Liu
Journal:  Front Immunol       Date:  2021-12-16       Impact factor: 7.561

Review 5.  Regulatory Cells in Multiple Sclerosis: From Blood to Brain.

Authors:  Leticia Calahorra; Celia Camacho-Toledano; Mari Paz Serrano-Regal; María Cristina Ortega; Diego Clemente
Journal:  Biomedicines       Date:  2022-02-01

Review 6.  B cells in central nervous system disease: diversity, locations and pathophysiology.

Authors:  Rajiv W Jain; V Wee Yong
Journal:  Nat Rev Immunol       Date:  2021-12-13       Impact factor: 108.555

Review 7.  The Role of B Cells in Primary Progressive Multiple Sclerosis.

Authors:  Jameson P Holloman; Robert C Axtell; Nancy L Monson; Gregory F Wu
Journal:  Front Neurol       Date:  2021-06-07       Impact factor: 4.086

8.  Cnp Promoter-Driven Sustained ERK1/2 Activation Increases B-Cell Activation and Suppresses Experimental Autoimmune Encephalomyelitis.

Authors:  Marisa A Jeffries; Alison E Obr; Kelly Urbanek; Sharyl L Fyffe-Maricich; Teresa L Wood
Journal:  ASN Neuro       Date:  2020 Jan-Dec       Impact factor: 5.200

Review 9.  Cross-Talk of the CNS With Immune Cells and Functions in Health and Disease.

Authors:  Agata Matejuk; Arthur A Vandenbark; Halina Offner
Journal:  Front Neurol       Date:  2021-05-31       Impact factor: 4.003

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.